CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Kim A. Reiss(University of Pennsylvania), Mathew G. Angelos(University of Pennsylvania), E. Claire Dees(University of North Carolina at Chapel Hill), Yuan Yuan(Cedars-Sinai Medical Center), Naoto T. Ueno(University of Hawaiʻi at Mānoa), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Melissa L. Johnson(Cancer Research Institute), Joseph Chao(City of Hope), Olga Shestova(University of Pennsylvania), Jonathan S. Serody(University of North Carolina at Chapel Hill), Maggie Schmierer(Carisma Therapeutics (United States)), Madison Kremp(Carisma Therapeutics (United States)), Michael Ball(Carisma Therapeutics (United States)), Rehman Qureshi(Carisma Therapeutics (United States)), Benjamin H. Schott(Carisma Therapeutics (United States)), Poonam Sonawane(Carisma Therapeutics (United States)), Sabrina Ceeraz DeLong(Carisma Therapeutics (United States)), Melissa Christiano(Carisma Therapeutics (United States)), Ramona F. Swaby(Carisma Therapeutics (United States)), Sascha Abramson(Carisma Therapeutics (United States)), Ken Locke(Carisma Therapeutics (United States)), Débora Barton(Carisma Therapeutics (United States)), Eugene P. Kennedy(Carisma Therapeutics (United States)), Saar Gill(University of Pennsylvania), Daniel J. Cushing(Carisma Therapeutics (United States)), Michael Klichinsky(Carisma Therapeutics (United States)), Thomas Condamine(Carisma Therapeutics (United States)), Yara Abdou(University of North Carolina at Chapel Hill)
Cited by 175
Abstract
Related Papers
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Yoav Benjamini, Yosef Hochberg|Journal of the Royal Statistical Society Series B (Statistical Methodology)|1995|108k